Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study

Jiaqiang Wang 1
Shilei Gao 1
Yonghao Yang 2
Xu Liu 1
Peng Zhang 1
Shuping Dong 1
Xin Wang 1
Weitao Yao 1

1Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan Province, 450008, People’s Republic of China; 2Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan Province, 450008, People’s Republic of China

Purpose: Advanced clear cell sarcoma (CCS) is a rare subtype of sarcoma with few effective treatments. Evidence shows that apatinib is efficacious and safe for CCS. This study aimed to assess the safety and efficacy of apatinib and/or camrelizumab (a PD-1 inhibitor) in treating advanced CCS.

Methods: We retrospectively reviewed 12 patients with advanced CCS who received apatinib and/or camrelizumab therapy between November 2018 and July 2021. Standard descriptive statistics were employed for continuous variables and categorical variables (number and percentage).

Results: Of the 12 CCS patients, 3 had a partial response (PR), and 4 had stable disease (SD). Among the 5 patients treated with apatinib monotherapy, 1 PR and 2 SD were found, and the addition or replacement of camrelizumab after progressive disease (PD) did not work. In the 4 patients who received apatinib plus camrelizumab combination therapy, 1 PR and 1 SD were found. All 3 patients who received camrelizumab first had PD, and 1 PR and 1 SD were found after adding apatinib. Grade 3 or 4 adverse events were significantly more common in the apatinib plus camrelizumab combination therapy than in the apatinib or camrelizumab monotherapy, and these included increased aspartate aminotransferase and increased alanine aminotransferase levels.

Conclusion: Apatinib has promising effectiveness for CCS. Camrelizumab efficacy for the treatment of clear cell sarcoma is inconclusive. The efficacy of apatinib and PD-1 inhibitors in CCS need to be further investigated in prospective clinical trials.

Keywords: clear cell sarcoma, apatinib, camrelizumab, sarcoma, tyrosine kinase inhibitor, PD-1 inhibitor

Introduction

Clear cell sarcoma (CCS) is an extremely rare sarcoma, accounting for approximately 1% of all soft tissue sarcomas (STSs), with approximately 400 new cases in China each year. 1,2 CCS was originally named soft tissue melanoma because of its immunohistochemical, ultrastructural, and genomic predisposition to melanocyte differentiation. 3,4 This designation is now obsolete because pathologists can now accurately identify clear cell sarcomas. 1,5 CCS may originate anywhere in the body but more often in the extremities. The initial symptom is usually a slowly increasing painless mass with lymph node metastasis in the early to middle stages. 3,4,6 Once lymph node metastasis occurs, CCS progression begins to accelerate, followed by widespread metastases to the lungs and/or other organs of the body. 7,8 Surgery is the main treatment for early and...
middle stages CCS. CCS is insensitive to chemotherapy and radiotherapy, resulting in a poor prognosis for advanced CCS, with a median overall survival (OS) of less than 1 year.

With the large-scale marketing and clinical application of targeted drugs, CCS, like other STSs, has many new treatment options. Of the many targeted therapies, the most influential are multi-target tyrosine kinase inhibitors (TKIs), and PD-1 inhibitors. Apatinib is a multi-target TKI that is marketed in China. It is widely used off-label for treating sarcomas in China, and its efficacy has been repeatedly confirmed. Camrelizumab is a PD-1 inhibitor marketed in China and is also widely used off-label for the treatment of sarcomas.

As a major sarcoma diagnosis and treatment center in a province with a population of nearly 100 million in central China, we have rich experience in sarcoma diagnosis and treatment. We have also treated sarcoma patients with multi-targeted TKIs and/or PD1 inhibitors, some of which were CCS patients. In this study, we retrospectively collected and analyzed the clinical data of CCS patients who received either apatinib or camrelizumab, aimed to assess the safety and efficacy of apatinib and/or camrelizumab in the treatment of advanced CCS.

Methods

Patients

We retrospectively collected and analyzed the medical data of CCS patients treated with apatinib and/or camrelizumab between November 2018 and July 2021 at our institution. Written informed consent for off-label treatment was obtained from all the patients before treatment. This study was performed in accordance with the principles of the Declaration of Helsinki and the Institutional Review Board of the Affiliated Cancer Hospital of Zhengzhou University. The eligibility criteria were as follows: (1) histologically-confirmed CCS; (2) complete clinical data; (3) inoperable disease progression (recurrence or primary); (4) treatment with apatinib and/or camrelizumab; and (5) the target lesions were measurable according to the response evaluation criteria in solid tumors (RECIST).

Evaluation of Safety and Efficacy

Baseline information was collected and analyzed, including age, sex, presentation status of lesions, tumor location, tumor size, previous treatment history, date and dose of initial apatinib and camrelizumab administration, treatment interruption or discontinuation, and progression time. Efficacy was evaluated according to the RECIST criteria every 6 weeks using magnetic resonance imaging or computed tomography. Anti-tumor efficacy was categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), according to the RECIST criteria. Response duration and adverse events (AEs) were also evaluated. Response duration was defined as the time from the occurrence of CR or PR to treatment to the occurrence of PD or death. AEs were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

Statistical Analysis

This study was a descriptive analysis. All data were analyzed using SPSS 21.0, and the corresponding figure was drawn using GraphPad Prism (version 8). Quantitative variables are presented as numerical values (percentages) and medians (ranges). Standard descriptive statistics were employed for continuous and categorical variables (numbers and percentages) to characterize patient demographics, treatment response, and AEs. Group-wise comparison was performed using the Chi-square test. All statistical analyses were two-sided, and p<0.05 was considered statistically significant. The last date for the assessment of clinical outcomes was July 31, 2021.

Results

Patient Characteristics

From November 2018 to July 2021, a total of 12 patients with advanced CCS treated with apatinib and/or camrelizumab were identified. Basic patient characteristics are shown in Table 1. The cohort included 6 men and 6 women. The average patient age was 42.00 ± 14.73 years. All patients had an Eastern Cooperative Oncology Group performance status of 0 or 1 and stage IV disease. The primary tumor site varied greatly and was distributed throughout the body. However, it was mainly in the extremities (as the primary tumor location was the thigh in two patients, hand in three patients, forearm in two patients, axillary region in one patient, scapular region in one patient, gluteal region in one patient, lower leg in one patient, and upper arm in one patient). Lymph node metastasis occurred first in all patients, and all patients had previously received doxorubicin or doxorubicin plus ifosfamide chemotherapy (Table 1).

Five of the 12 CCS patients started treatment with apatinib monotherapy. After PD, two patients received a combination therapy of apatinib plus camrelizumab, and two patients discontinued apatinib and were replaced with camrelizumab.
monotherapy. Three patients started with camrelizumab monotherapy and changed to apatinib plus camrelizumab combination therapy when PD occurred. Four patients received apatinib plus camrelizumab combination therapy.

**Treatment Outcomes**

Of the 12 CCS patients, none had a CR. Three patients had PR, and four patients had SD (Table 1, Figure 1). As shown in Table 1, of the 3 patients with PR, patient 1 developed PR after apatinib monotherapy, and the response lasted for 8.5 months, and camrelizumab was ineffective after PD. Patient 7 had no response to camrelizumab monotherapy and had PR after adding apatinib, and the response lasted 11.5 months. Patient 12 achieved PR after treatment with apatinib plus camrelizumab combination therapy, and the response lasted 5 months. The median progression-free survival of all the 12 patients was 3 months (95% CI, 1.3 – NA months) (Figure 2).

Table 2 summarizes the effects of different administration sequences. Among the five patients treated with apatinib monotherapy, 1 PR and 2 SD were identified, and the addition or replacement of camrelizumab after PD did not work. In the

### Table 1: Patient Demographics and Characteristics

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Sex</th>
<th>Age (Years)</th>
<th>ECOG PS</th>
<th>Stage</th>
<th>Primary Site</th>
<th>Metastatic Site</th>
<th>Previous Treatment</th>
<th>Sequence of Administration</th>
<th>Best Response</th>
<th>Response Duration (Months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Female</td>
<td>30</td>
<td>0</td>
<td>IV</td>
<td>Thigh</td>
<td>Lymph nodes</td>
<td>A+I</td>
<td>Start with AP, and add C after PD</td>
<td>PR</td>
<td>8.5</td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
<td>27</td>
<td>0</td>
<td>IV</td>
<td>Hand</td>
<td>Lung</td>
<td>A+I</td>
<td>Start with AP, and add C after PD</td>
<td>PD</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>Male</td>
<td>43</td>
<td>0</td>
<td>IV</td>
<td>Hand</td>
<td>Lymph nodes</td>
<td>A+I</td>
<td>Start with AP, and switched to C after PD</td>
<td>SD</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>Female</td>
<td>58</td>
<td>I</td>
<td>IV</td>
<td>Forearm</td>
<td>Lymph nodes</td>
<td>A+I</td>
<td>Start with AP, and switched to C after PD</td>
<td>SD</td>
<td>6.5</td>
</tr>
<tr>
<td>5</td>
<td>Female</td>
<td>49</td>
<td>0</td>
<td>IV</td>
<td>Thigh</td>
<td>Lymph nodes</td>
<td>A+I</td>
<td>Start with AP, and switched to C after PD</td>
<td>PD</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>Male</td>
<td>62</td>
<td>0</td>
<td>IV</td>
<td>Axillary region</td>
<td>Lymph nodes</td>
<td>A</td>
<td>Start with C, and add AP after PD</td>
<td>PD</td>
<td>0</td>
</tr>
<tr>
<td>7</td>
<td>Male</td>
<td>28</td>
<td>I</td>
<td>IV</td>
<td>Scapular region</td>
<td>Lymph nodes</td>
<td>A</td>
<td>Start with C, and add AP after PD</td>
<td>PR</td>
<td>11.5</td>
</tr>
<tr>
<td>8</td>
<td>Male</td>
<td>61</td>
<td>I</td>
<td>IV</td>
<td>Forearm</td>
<td>Lymph nodes</td>
<td>A+I</td>
<td>Start with C, and add AP after PD</td>
<td>SD</td>
<td>6</td>
</tr>
<tr>
<td>9</td>
<td>Male</td>
<td>42</td>
<td>I</td>
<td>IV</td>
<td>Gluteal region</td>
<td>Lymph nodes</td>
<td>A+I</td>
<td>AP in parallel with C</td>
<td>PD</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>Female</td>
<td>54</td>
<td>0</td>
<td>IV</td>
<td>Lower leg</td>
<td>Lymph nodes</td>
<td>A</td>
<td>AP in parallel with C</td>
<td>PD</td>
<td>0</td>
</tr>
<tr>
<td>11</td>
<td>Male</td>
<td>21</td>
<td>0</td>
<td>IV</td>
<td>Upper arm</td>
<td>Lymph nodes</td>
<td>A+I</td>
<td>AP in parallel with C</td>
<td>SD</td>
<td>2</td>
</tr>
<tr>
<td>12</td>
<td>Female</td>
<td>29</td>
<td>0</td>
<td>IV</td>
<td>Hand</td>
<td>Lymph nodes</td>
<td>A+I</td>
<td>AP in parallel with C</td>
<td>PR</td>
<td>5</td>
</tr>
</tbody>
</table>

**Abbreviations:** ECOG PS, Eastern Cooperative Oncology Group performance status; A, adriamycin; I, ifosfamide; AP, apatinib; C, camrelizumab; PD, progressive disease; PR, partial response; SD, stable disease.
four patients who received apatinib plus camrelizumab combination therapy, 1 PR and 1 SD were identified. All three patients who received camrelizumab first had PD, and 1 PR and 1 SD were found after adding apatinib.

**Toxicity and Safety**

Overall, treatment with apatinib and camrelizumab was safe (Table 3). Most patients experienced grades 1 or 2 AEs, a few patients experienced grades 3 or 4 AEs, and no drug-related deaths occurred. To better describe AEs with apatinib and camrelizumab, we divided the patients into the apatinib group (5 patients receiving apatinib monotherapy), the camrelizumab group (6 patients receiving camrelizumab), and the apatinib plus camrelizumab group (9 patients receiving the combination therapy) (Table 3). Grade 3 or 4 AEs were significantly more common in the apatinib plus camrelizumab group than in the apatinib or camrelizumab group, and these included increased aspartate aminotransferase (p=0.023) and increased alanine aminotransferase (p=0.017) (Table 3).

**Discussion**

In this study, we retrospectively reviewed and analyzed the clinical data of 12 CCS patients who received apatinib and/or camrelizumab, we divided the patients into the apatinib group (5 patients receiving apatinib monotherapy), the camrelizumab group (6 patients receiving camrelizumab), and the apatinib plus camrelizumab group (9 patients receiving the combination therapy) (Table 3). Grade 3 or 4 AEs were significantly more common in the apatinib plus camrelizumab group than in the apatinib or camrelizumab group, and these included increased aspartate aminotransferase (p=0.023) and increased alanine aminotransferase (p=0.017) (Table 3).

**Table 2** Patient Responses to Different Treatment

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Number of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>AP (n=5)</td>
<td>CR: 0</td>
</tr>
<tr>
<td>C after the PD of AP (n=3)</td>
<td>CR: 0</td>
</tr>
<tr>
<td>C + AP after the PD of AP (n=2)</td>
<td>CR: 0</td>
</tr>
<tr>
<td>C (n=3)</td>
<td>CR: 0</td>
</tr>
<tr>
<td>C + AP after the PD of C (n=3)</td>
<td>CR: 0</td>
</tr>
<tr>
<td>C + AP (n=4)</td>
<td>CR: 0</td>
</tr>
</tbody>
</table>

**Abbreviations**: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; AP, apatinib; C, camrelizumab.
camrelizumab. Three patients achieved PR with a response time of 8.5 months, 11.5 months, and 5 months, respectively. Furthermore, the biggest safety problem of apatinib combined with camrelizumab was the increase in aspartate aminotransferase and alanine aminotransferase levels.

Including this study, CCS has been reported to respond to treatment with apatinib, sunitinib, anlotinib, and pazopanib.\textsuperscript{15,24,25} This phenomenon is worthy of further research. These target drugs belong to a class of multi-target TKIs with VEGFR (vascular endothelial growth factor)-2 as the main target, and their targets are shown in Table 4. Based on the aggregated results, we can conclude that VEGFRs are an important set of targets for the treatment of CCS. Therefore, it can be inferred that other multi-target TKIs with VEGFR-2 as the main target can also achieve some efficacy in treating CCS. Moreover, a 2017 clinical trial showed that crizotinib also had some effect on CCS.\textsuperscript{14} The main target of crizotinib was MET (Table 4). This suggests that MET may also be a key target for CCS therapy. Thus, we conclude that another multi-target TKI, cabozantinib, may be more effective in treating CCS because it has the most comprehensive targets, including VEGFRs and MET (Table 4). Prospective clinical trials of cabozantinib for CCS are warranted.

In this study, PR was observed in patients receiving apatinib alone or in combination, while no effective response was observed in patients receiving camrelizumab alone or in combination with camrelizumab after apatinib resistance. This confirms that apatinib does work in a subset of CCS patients but does not confirm the effectiveness of camrelizumab. We suspected that camrelizumab did not work. The results of numerous clinical trials to date indicate that PD-1 inhibitor monotherapy has minimal effectiveness in STSs.\textsuperscript{16,31,32} Although the combination of multi-target TKIs and PD-1 inhibitors may improve the efficacy of these two drugs in STS,\textsuperscript{33,34} there are many subtypes of STS, and the combination of multi-target TKIs and PD-1 inhibitors is only effective in a few subtypes of STS. Moreover, no evidence has been reported that PD-1

### Table 3 Grade 3 or 4 Adverse Events

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Apatinib (n=5)</th>
<th>Camrelizumab (n=6)</th>
<th>Apatinib Plus Camrelizumab (n=9)</th>
<th>( P )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0.539</td>
</tr>
<tr>
<td>Hand-foot syndrome</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0.539</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0.649</td>
</tr>
<tr>
<td>Increased aspartate aminotransferase</td>
<td>0</td>
<td>1</td>
<td>6</td>
<td>0.023</td>
</tr>
<tr>
<td>Increased alanine aminotransferase</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>0.017</td>
</tr>
<tr>
<td>Decreased neutrophil count</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0.257</td>
</tr>
<tr>
<td>Increased blood bilirubin</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0.257</td>
</tr>
</tbody>
</table>

**Note:** Data are presented as numbers.

### Table 4 Sensitive Targets of Apatinib, Pazopanib, Anlotinib, Sunitinib, Crizotinib, and Cabozantinib

<table>
<thead>
<tr>
<th>TKIs</th>
<th>PDGFR\textsuperscript{a}</th>
<th>PDGFR\textsuperscript{b}</th>
<th>FGFR1</th>
<th>MET \textsuperscript{b}</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>VEGFR1</td>
<td>VEGFR2</td>
<td>VEGFR3</td>
<td>KIT</td>
<td>RET</td>
</tr>
<tr>
<td>Apatinib</td>
<td>70</td>
<td>1</td>
<td>–</td>
<td>429</td>
<td>13</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>10</td>
<td>30</td>
<td>47</td>
<td>74</td>
<td>–</td>
</tr>
<tr>
<td>Anlotinib</td>
<td>26.9</td>
<td>0.2</td>
<td>0.7</td>
<td>14.8</td>
<td>–</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>71.5</td>
<td>4</td>
<td>15.7</td>
<td>11</td>
<td>72</td>
</tr>
<tr>
<td>Crizotinib</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Cabozantinib</td>
<td>12</td>
<td>0.035</td>
<td>6</td>
<td>4.6</td>
<td>5.2</td>
</tr>
</tbody>
</table>

**Abbreviations:** TKI, tyrosine kinase inhibitor; RTKs, receptor tyrosine kinases.
inhibitors alone or in combination with other therapies show activity in CCS. In summary, based on the results of this study and the currently available evidence, we speculate that the efficacy of PD-1 inhibitors in CCS is minimal.

This study suggests the safety of apatinib in combination with camrelizumab for the treatment of CCS. In this study, AEs were rare when apatinib or camrelizumab was used alone. The incidence of grades 3 or 4 AEs increased significantly when apatinib was combined with camrelizumab. The most common grade 3 and above AEs were increased transaminase levels. These AEs caused patients to be unable to continue using camrelizumab and require glucocorticoids to inhibit the pharmacological effects of camrelizumab. This may also explain why apatinib plus camrelizumab was not effective in this study.

It should be noted that patients treated with the combination regimen of apatinib and camrelizumab did not present with severe aminotransferase elevations in other tumor species. This may be related to the higher dose of apatinib used in this study (500 mg/day in this study versus 250–375 mg/day in other studies). This suggests that we need to lower the dose of apatinib in future studies or when using this combination regimen.

There were several limitations to this study. First, this study was retrospective in nature, with a small sample size and a lack of a control group. These limitations were due to the rareness of CCS. Second, the disordered use of drugs. Treatment with camrelizumab was unplanned in all cases in this study. We do not yet know the optimal order and scenarios for using multi-target TKIs and PD-1 inhibitors. This is a problem that doctors around the world are now facing when treating sarcomas. This needs to be confirmed by a large number of prospective clinical trials.

**Conclusion**

Apatinib has promising effectiveness for CCS. The efficacy of camrelizumab for the treatment of clear cell sarcoma is inconclusive. The efficacy of apatinib and PD-1 inhibitors in CCS needs to be further investigated in prospective clinical trials.

**Ethical Statement**

This retrospective study was approved by the Ethics Committee of the Henan Cancer Hospital in China, and written informed consent was obtained from each patient prior to all treatment procedures. Patients were informed that the medical records were stored by the hospital and potentially used for scientific research and that privacy would be maintained. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Author Contributions**

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Disclosure**

The authors declare they have no competing interests in this work.

**References**


Cancer Management and Research

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal

Cancer Management and Research 2021:13

9005